The Life Sciences team advised Cerevel Therapeutics (Nasdaq: CERE) on its underwritten public offering of 14,000,000 shares of common stock at a public offering price of $25 per share. The gross proceeds to Cerevel of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $350 million. In addition, Cerevel has granted the underwriters a 30-day option to purchase an additional 2,100,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions.
Cerevel is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity.
The Goodwin team was led by Stuart Cable, Nicole Daley, Karin Yoo, and Eugenia Cecala, and included Julie Tibbets, Elizabeth Mulkey, Heath Ingram, Alex Apostolopoulos, and Ettore Santucci.
For more details, read the press release and article in Endpoints.